DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
| Revenue (TTM) | $14.01B |
| Gross Profit (TTM) | $4.53B |
| EBITDA | $2.83B |
| Operating Margin | 16.10% |
| Return on Equity | 88.50% |
| Return on Assets | 7.52% |
| Revenue/Share (TTM) | $204.69 |
| Book Value | $-11.96 |
| Price-to-Book | 21.63 |
| Price-to-Sales (TTM) | 0.82 |
| EV/Revenue | 1.742 |
| EV/EBITDA | 8.80 |
| Quarterly Earnings Growth (YoY) | 55.80% |
| Quarterly Revenue Growth (YoY) | 5.20% |
| Shares Outstanding | $63.80M |
| Float | $33.94M |
| % Insiders | 46.91% |
| % Institutions | 48.39% |
Volatility is currently expanding
The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.
With AI companies—and related chip stocks—driving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momentum it seems to have. Fortunately, a number of non-AI stocks have stood out for their strong performance throughout the first part of 2026.
President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to DVA stock based on the movements in the options market lately.
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DVA and any ticker you trade — then tracks every position and per-strategy win rate.
